A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
GVHD were marginally lower after HLA matched or mismatched UCB transplants than after allele-matched BM. Notably, leukemia-free survival (LFS) rates at 5 years were comparable between those receiving allele matched BM (38%) and 1 locus high cell dose (41%), 1 locus low cell dose (37%) or 2 loci (33%) HLA mismatched UCB. The observed higher LFS rate (60%) after HLA matched UCB transplant requires validation in a larger cohort. These results in LFS are in part explained by differences in risks ofdoi:10.1016/j.bbmt.2007.08.014 fatcat:v5h7byenend4por4au5jxzdbjq